Business Wire

IFF and Master Perfumer Carlos Benaim Celebrate 50 Years Together


Regulatory News:

This press release features multimedia. View the full release here:

Carlos Benaim (Photo: Business Wire)

Carlos Benaim (Photo: Business Wire)

International Flavors & Fragrances Inc. (NYSE: IFF) (Euronext Paris: IFF), a leading innovator of sensory experiences that move the world, is honoring the 50th anniversary of its Master Perfumer, Carlos Benaim with a series of celebrations throughout the next year.

“It is impossible to overstate the importance of Carlos’ contributions not only to IFF, but to the whole industry,” said Andreas Fibig, IFF Chairman and CEO. “The history of perfumery over the last 50 years has been shaped in many ways by the hand of Carlos Benaim. I consider it our greatest fortune that he chose to make his career with IFF.”

Born in Morocco and the son of a pharmacist, Mr. Benaim was intrigued by the botanicals and essential oils used in his father’s business. He studied chemistry at the University of Toulouse and Ecole Nationale Superíeure de Chimie de Toulouse in France. After answering an ad for a position at IFF in 1967, his year of training culminated with an apprenticeship with the legendary perfumer Ernest Shiftan – the “father of perfumery” at IFF – and later, trained with Bernard Chant. In the ensuing years, Mr. Benaim created hundreds of iconic fragrances for men and women, nine of which won the industry’s highest honor – the Fragrance Foundation Award. In 2002, he received a Lifetime Achievement Award from the American Society of Perfumers and in 2014, he was recognized by the Fragrance Foundation with a Perfumer of the Year Lifetime Achievement Award. In 2013, he was named IFF’s first-ever Master Perfumer in recognition of his creativity, mastery of his art, market success, and exceptional customer relationships.

Nicolas Mirzayantz, Group President, Fragrances, said, “Carlos, a true gentleman in every sense of the word, is also a genius of perfumery who has selflessly shared his knowledge by coaching, mentoring, and inspiring countless perfumers over the years. A master of natural ingredients, Carlos is at the cutting edge of his creativity and innovation and I’m excited, as always, to see what successful and iconic fragrances he will create for us – and our customers – in the future. His passion for his art, the industry, and our customers is unparalleled. Beyond the extraordinary pleasure of having Carlos as my colleague, I am also proud to call him a dear and lifelong friend.”

Mr. Benaim’s creations and co-creations include Polo Green and Polo Blue by Ralph Lauren; Euphoria by Calvin Klein; Eternity for Men by Calvin Klein; Herrera for Men by Carolina Herrera; Solo by Loewe; White Diamonds by Elizabeth Taylor; Fierce by Abercrombie & Fitch; Jasmin Noir by Bulgari; Very Irresistible Givenchy by Givenchy; Prada Amber by Prada; Armani Code for Women by Giorgio Armani; Flowerbomb, Spicebomb, and Antidote by Viktor & Rolf; Eau De Magnolia by Carlos Benaim for Frederic Malle; and many others.

Mr. Benaim reflected, “I want to talk not about what I did for IFF, but what IFF did for me. IFF trained me to be a perfumer, opened the doors of the major customers worldwide, and helped at every step along my path toward a successful international career. IFF gave me creative freedom. Fifty years later, with all the clarity of hindsight, I know that finding IFF was one of the luckiest accidents of my life.”

Meet IFF

International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) is a leading innovator of sensorial experiences that move the world. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for exploration drives us to co-create unique products that consumers taste, smell, or feel in fine fragrances and beauty, detergents and household goods, as well as beloved foods and beverages. Our 7,400 team members globally take advantage of leading consumer insights, research and development, creative expertise, and customer intimacy to develop differentiated offerings for consumer products. Learn more at, Twitter , Facebook, Instagram, and LinkedIn.

Contact information

International Flavors & Fragrances Inc.
Michael DeVeau, 212-708-7164
VP, Corporate Strategy, Investor Relations & Communications

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 15:52Tiedote

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 15:50Tiedote

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 15:46Tiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 15:00Tiedote

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on

ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe23.3.2018 14:27Tiedote

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. The 2-drug regimen comprises dolutegravir 50mg (ViiV Healthcare) and rilpivirine 25mg (Janssen Sciences Ireland UC). Deborah Waterhouse, Chief Executive Officer at ViiV Healthcare commented: “Today is an important milestone for people living with HIV in Europe. It takes us a step closer to offering the first, single-pill, 2-drug regi

Sofinnova Partners Leads SafeHeal’s €6 Million Series a Financing Round23.3.2018 10:00Tiedote

SafeHeal, an early-stage medtech company specialized in digestive surgery and focused on the development of the Colovac device, announces today that it has closed a €6 million Series A financing round led by Sofinnova Partners. Based in Paris, SafeHeal develops an innovative digestive anastomosis protection device, called Colovac, designed to reduce complications and obviate the need for ostomies for colectomy patients. This technology consists of a minimally invasive and fully reversible implant that remains in place until the body’s natural healing and tissue repair processes are complete, for approximately two weeks, after which it is removed. SafeHeal’s device has the potential to radically transform the market while significantly improve patients’ quality of life by enabling them to resume their normal life without having to bear an artificial anus and wear ostomy pouches for several months. About 270,000 colectomy patients receive an ostomy every year in Europe and the USA, repre

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme